Sangamo Biosciences (SGMO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Sangamo BioSciences Reports Fourth Quarter And Full Year 2015 Financial Results
February 9, 2016 4:04 PM ESTRICHMOND, Calif., Feb. 9, 2016 /PRNewswire/ --Â Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its fourth quarter and full year 2015 financial results and accomplishments.
"2015 was an important and very productive year for Sangamo, and we enter 2016 poised to initiate the first human clinical trials of in vivo therapeutic genome editing," said Edward Lanphier, Sangamo's president and chief executive officer. "Our zinc finger nuclease (ZFN) technology leads the therapeutic genome editing... More
